A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. (Q39374283)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

based on heuristic

inferred from title

Attila A Seyhan

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Usha Varadarajan

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sung Choe

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Wei Liu

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Terence E Ryan

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

23 March 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Molecular BioSystems

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1553-1570

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22446932%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

New approaches to molecular cancer therapeutics

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Antitumor activity of HER-2 inhibitors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The consensus coding sequences of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Perspectives: Other ErbB2-Targeted Therapies

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Why is cancer drug discovery so difficult?

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Integrated functional, gene expression and genomic analysis for the identification of cancer targets

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

RNAi screening for the discovery of novel modulators of human disease

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A loss-of-function RNA interference screen for molecular targets in cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Dissecting cancer pathways and vulnerabilities with RNAi

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cancer proliferation gene discovery through functional genomics.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Normalization of cDNA microarray data

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The genetic landscape of the childhood cancer medulloblastoma

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Bcl-G, a novel pro-apoptotic member of the Bcl-2 family

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

New apoptosis drugs face critical test

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

The genomic landscapes of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Mutations in TRIOBP, which encodes a putative cytoskeletal-organizing protein, are associated with nonsyndromic recessive deafness

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Squalene synthase inhibition: a novel target for the management of dyslipidemia

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

FoxP4, a novel forkhead transcription factor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability.

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Sodium ion channel mutations in glioblastoma patients correlate with shorter survival

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A pivotal role of cyclic AMP-responsive element binding protein in tumor progression

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Profiling essential genes in human mammary cells by multiplex RNAi screening

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Minimizing the risk of reporting false positives in large-scale RNAi screens

1 reference

https://api.crossref.org/works/10.1039%2FC2MB05512K

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39374283&oldid=1517028790"